US20020164782A1
(en)
|
1999-02-10 |
2002-11-07 |
Gregory Richard J. |
Adenovirus vectors for gene therapy
|
US5670488A
(en)
*
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
US8153602B1
(en)
*
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
WO1993012240A1
(en)
*
|
1991-12-17 |
1993-06-24 |
The Regents Of The University Of California |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
|
WO1994005782A1
(en)
*
|
1992-09-10 |
1994-03-17 |
Trustees Of Tufts College |
In vivo production of transgenic organ by introducing the transgene via lumen
|
EP0702516A4
(de)
|
1993-06-01 |
1998-04-22 |
Life Technologies Inc |
Genetische immunisierung mit kationischen lipiden
|
US5688677A
(en)
*
|
1993-10-13 |
1997-11-18 |
Genzyme Corporation |
Deoxyribonucleic acids containing inactivated hormone responsive elements
|
WO1995010538A1
(en)
*
|
1993-10-15 |
1995-04-20 |
The University Of North Carolina At Chapel Hill |
Dna encoding the human p2u receptor and null cells expressing p2u receptors
|
US6887856B1
(en)
|
1993-10-15 |
2005-05-03 |
University Of Pittsburgh |
Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
|
FR2711523B1
(fr)
|
1993-10-26 |
1996-02-16 |
Transgene Sa |
Procédé de préparation d'un aérosol viral.
|
US5614551A
(en)
*
|
1994-01-24 |
1997-03-25 |
The Johns Hopkins University |
Inhibitors of fatty acid synthesis as antimicrobial agents
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
FR2727679B1
(fr)
*
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
US6383814B1
(en)
*
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
PT799058E
(pt)
*
|
1994-12-24 |
2003-11-28 |
Univ Cambridge Tech |
Melhoramentos na funcao endometrica ou com ela relacionados
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US5935568A
(en)
*
|
1995-05-18 |
1999-08-10 |
National Jewish Medical & Research Center |
Gene therapy for effector cell regulation
|
AU771241B2
(en)
*
|
1995-06-07 |
2004-03-18 |
Tekmira Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6040296A
(en)
*
|
1995-06-07 |
2000-03-21 |
East Carolina University |
Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6025339A
(en)
*
|
1995-06-07 |
2000-02-15 |
East Carolina University |
Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
|
JP4335310B2
(ja)
*
|
1995-06-07 |
2009-09-30 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
|
US5756122A
(en)
*
|
1995-06-07 |
1998-05-26 |
Georgetown University |
Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
US5705385A
(en)
*
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
AU7078396A
(en)
*
|
1995-09-27 |
1997-04-30 |
Regents Of The University Of California, The |
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
|
US5869715A
(en)
*
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
US6121247A
(en)
*
|
1996-03-29 |
2000-09-19 |
The Johns Hopkins University |
Therapy for allergic diseases
|
US6156567A
(en)
*
|
1996-07-03 |
2000-12-05 |
Merial |
Truncated transcriptionally active cytomegalovirus promoters
|
CA2265838A1
(en)
|
1996-09-12 |
1998-03-19 |
Alain Rolland |
Compositions and methods for pulmonary gene delivery
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6365575B1
(en)
|
1996-10-24 |
2002-04-02 |
Vanderbilt University |
Gene delivery and expression in areas inaccessible to direct protein delivery
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US5981575A
(en)
*
|
1996-11-15 |
1999-11-09 |
Johns Hopkins University, The |
Inhibition of fatty acid synthase as a means to reduce adipocyte mass
|
US6034072A
(en)
*
|
1997-02-10 |
2000-03-07 |
Genemedicine, Inc. |
IL-2 gene expression and delivery systems and uses
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US5965542A
(en)
*
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
US20030229040A1
(en)
*
|
1997-03-21 |
2003-12-11 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US7262173B2
(en)
*
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
US6559129B1
(en)
*
|
1997-03-21 |
2003-05-06 |
Georgetown University |
Cationic liposomal delivery system and therapeutic use thereof
|
US6126965A
(en)
*
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
US5958894A
(en)
*
|
1997-04-04 |
1999-09-28 |
Megabios Corporation |
Amphiphilic biguanide derivatives
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
CA2205076A1
(en)
|
1997-05-14 |
1998-11-14 |
Jim Hu |
Episomal expression cassettes for gene therapy
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
CA2297489A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US20050142126A1
(en)
*
|
1997-08-20 |
2005-06-30 |
Bernard Knoops |
Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
|
AU747438B2
(en)
|
1997-09-24 |
2002-05-16 |
Regents Of The University Of California, The |
Non-primate lentiviral vectors and packaging systems
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6433040B1
(en)
*
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
*
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
US7157098B1
(en)
*
|
1998-01-06 |
2007-01-02 |
Roman Perez-Soler |
Gene therapy of tumors using non-viral delivery system
|
TW520294B
(en)
*
|
1998-01-08 |
2003-02-11 |
Res Dev Foundation |
Stabilization of lipid: DNA formulations during nebulization
|
US6375980B1
(en)
*
|
1998-01-08 |
2002-04-23 |
Research Development Foundation |
Stabilization of lipid:DNA formulations during nebulization
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
DE69936444T3
(de)
|
1998-02-03 |
2012-05-10 |
Protiva Biotherapeutics Inc. |
Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
|
US6158431A
(en)
*
|
1998-02-13 |
2000-12-12 |
Tsi Incorporated |
Portable systems and methods for delivery of therapeutic material to the pulmonary system
|
US6221848B1
(en)
|
1998-05-11 |
2001-04-24 |
University Of Pittsburgh |
Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
|
EP1086116A4
(de)
*
|
1998-05-21 |
2004-03-17 |
Isis Pharmaceuticals Inc |
Zusammensetzungen und verfahren für den pulmonativen transport von nuklein-säuren
|
JP2002515513A
(ja)
*
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
核酸の肺送達のための組成物および方法
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
WO2000009525A2
(en)
*
|
1998-08-03 |
2000-02-24 |
East Carolina University |
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
|
AU766703B2
(en)
*
|
1998-11-12 |
2003-10-23 |
Frank G Pilkiewicz |
An inhalation system
|
EP1839648A3
(de)
*
|
1998-11-12 |
2007-11-21 |
Transave, Inc. |
Inhalationssystem
|
AU772847B2
(en)
|
1998-11-12 |
2004-05-06 |
Invitrogen Corporation |
Transfection reagents
|
US6855549B1
(en)
|
1998-11-23 |
2005-02-15 |
The University Of Iowa Research Foundation |
Methods and compositions for increasing the infectivity of gene transfer vectors
|
US6716810B1
(en)
*
|
1998-12-09 |
2004-04-06 |
Eleanor Roosevelt Institute |
Composition and method for regulation of body weight and associated conditions
|
ES2391225T3
(es)
|
1999-02-24 |
2012-11-22 |
North Carolina State University |
Compuestos para alterar la secreción mucosa
|
US8501911B2
(en)
*
|
1999-02-24 |
2013-08-06 |
Biomarck Pharmaceuticals, Ltd |
Methods of reducing inflammation and mucus hypersecretion
|
US7544772B2
(en)
|
2001-06-26 |
2009-06-09 |
Biomarck Pharmaceuticals, Ltd. |
Methods for regulating inflammatory mediators and peptides useful therein
|
JP2003515525A
(ja)
*
|
1999-04-06 |
2003-05-07 |
イースト カロライナ ユニバーシティ |
気管支収縮、肺炎、アレルギーおよびサーファクタント枯渇と関連する気道障害を治療するための、低アデノシンアンチセンスオリゴヌクレオチド、その組成物、キットならびにその方法
|
WO2000061184A2
(en)
*
|
1999-04-08 |
2000-10-19 |
Glenn Gregory M |
Dry formulation for transcutaneous immunization
|
WO2001021837A1
(en)
*
|
1999-09-23 |
2001-03-29 |
The General Hospital Corporation |
Methods for potentiating antisense rna techniques
|
JP2003514855A
(ja)
|
1999-10-13 |
2003-04-22 |
チャコン,マルコ,エー. |
カロリー制限の効果を模倣した治療的介入
|
US7115712B1
(en)
*
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
US7919469B2
(en)
|
2000-02-24 |
2011-04-05 |
North Carolina State University |
Methods and compositions for altering mucus secretion
|
US7265088B1
(en)
|
2000-02-24 |
2007-09-04 |
North Carolina State University |
Method and compositions for altering mucus secretion
|
US8404217B2
(en)
*
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
PT1280520E
(pt)
*
|
2000-05-10 |
2014-12-16 |
Novartis Ag |
Pós à base de fosfolípidos para administração de fármacos
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
AU2001280934A1
(en)
*
|
2000-07-28 |
2002-02-13 |
Alliance Pharmaceutical Corp. |
Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
|
ES2310201T3
(es)
*
|
2001-02-13 |
2009-01-01 |
Government Of The United States Of America, As Represented By The Secretary Of The Army |
Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
|
WO2002088318A2
(en)
*
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
RU2294192C2
(ru)
*
|
2001-05-30 |
2007-02-27 |
Дзе Скриппс Рисерч Инститьют |
Система доставки нуклеиновых кислот
|
AU2002323266B2
(en)
*
|
2001-08-20 |
2008-04-24 |
Transave, Inc. |
Method for treating lung cancers
|
EP1424898A4
(de)
*
|
2001-08-20 |
2008-04-02 |
Transave Inc |
Behandlung von karzinomen durch inhalation von stabilen platinhaltigen formulierungen
|
WO2003037302A1
(en)
*
|
2001-10-30 |
2003-05-08 |
Windsor J Brian |
Method and system for the co-isolation of cognate dna, rna and protein sequences and method for screening co-isolates for defined activities
|
US20040063654A1
(en)
*
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
CN101259289B
(zh)
*
|
2001-11-02 |
2012-05-30 |
嵌入治疗公司 |
用于rna干扰的治疗用途的方法及组合物
|
AU2002368202B2
(en)
*
|
2001-11-02 |
2008-06-05 |
Insert Therapeutics, Inc |
Methods and compositions for therapeutic use of RNA interference
|
AUPR894201A0
(en)
*
|
2001-11-19 |
2001-12-13 |
Women's And Children's Hospital |
Respiratory delivery for gene therapy and lentiviral delivery particle
|
SI1458360T1
(sl)
|
2001-12-19 |
2011-08-31 |
Novartis Ag |
Pulmonalno dajanje aminoglikozidov
|
WO2003075890A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Transave, Inc. |
Methods for entrapment of bioactive agent in a liposome or lipid complex
|
WO2004007664A2
(en)
*
|
2002-05-28 |
2004-01-22 |
Maxygen, Inc. |
Nucleic acid vectors
|
JP4722481B2
(ja)
|
2002-06-28 |
2011-07-13 |
プロティバ バイオセラピューティクス リミテッド |
リポソーム製造方法および装置
|
BRPI0313191A2
(pt)
*
|
2002-08-02 |
2016-11-08 |
Transave Inc |
composição e processo para produzir um agregado de platina e formulação farmacêutica
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
JP5118302B2
(ja)
*
|
2002-10-29 |
2013-01-16 |
トランセイブ, インク. |
抗感染剤の徐放
|
US7718189B2
(en)
*
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
KR20050067216A
(ko)
*
|
2002-11-01 |
2005-06-30 |
코핀 코포레이션 |
다중-영역의 수직 정렬 액정 디스플레이
|
DK2865385T3
(en)
|
2003-02-04 |
2016-12-19 |
Cornell Res Foundation Inc |
Applications of the aromatic-cationic peptide
|
BRPI0409911A
(pt)
|
2003-05-01 |
2006-04-25 |
Cornell Res Foundation Inc |
método para liberar uma molécula em uma célula, e, complexo carreador
|
WO2005020885A2
(en)
*
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
AU2003252493A1
(en)
*
|
2003-07-09 |
2005-01-28 |
Anges Mg, Inc. |
Pharmaceutical composition containing decoy and method of using the same
|
AU2004257373B2
(en)
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
WO2005023292A1
(en)
*
|
2003-09-03 |
2005-03-17 |
The General Hospital Corporation |
Methods of treating restenosis
|
JP4842821B2
(ja)
|
2003-09-15 |
2011-12-21 |
プロチバ バイオセラピューティクス インコーポレイティッド |
ポリエチレングリコール修飾脂質化合物およびその使用
|
PL1687066T3
(pl)
|
2003-11-14 |
2013-01-31 |
Brigham & Womens Hospital Inc |
Sposoby modulowania odporności
|
CN1914320A
(zh)
*
|
2003-12-03 |
2007-02-14 |
中外制药株式会社 |
利用哺乳类β肌动蛋白启动子的表达体系
|
US8592368B2
(en)
*
|
2003-12-19 |
2013-11-26 |
University Of South Florida |
JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
|
CA2554166C
(en)
|
2004-01-23 |
2014-07-29 |
Cornell Research Foundation, Inc. |
Methods for reducing oxidative damage
|
US20080063700A1
(en)
*
|
2004-01-23 |
2008-03-13 |
Keio University |
Support Accumulating In Injured Part In Vascular Channel
|
US20060019914A1
(en)
*
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
AU2005223654A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Transave, Inc. |
Administration of cisplatin by inhalation
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
CN101001633A
(zh)
*
|
2004-05-21 |
2007-07-18 |
特兰萨夫公司 |
肺病和肺病前期病症的治疗
|
JP4796062B2
(ja)
|
2004-06-07 |
2011-10-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
脂質封入干渉rna
|
EP1781593B1
(de)
|
2004-06-07 |
2011-12-14 |
Protiva Biotherapeutics Inc. |
Kationische lipide und verwendungsverfahren
|
EP1773857A4
(de)
|
2004-07-02 |
2009-05-13 |
Protiva Biotherapeutics Inc |
Das immunsystem stimulierende sirna-moleküle und anwendungen davon
|
US20060051405A1
(en)
*
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
US20060045849A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Farhan Taghizadeh |
Method of customizing the fragrance of nasal medications
|
CA2584673A1
(en)
*
|
2004-11-08 |
2006-05-26 |
Transave, Inc. |
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
US20060134189A1
(en)
*
|
2004-11-17 |
2006-06-22 |
Protiva Biotherapeutics, Inc |
siRNA silencing of apolipoprotein B
|
EP2399599A3
(de)
|
2005-01-20 |
2012-04-18 |
Biomarck Pharmaceuticals, Ltd. |
Muzinhypersektretionsinhibitoren und Verwendungsverfahren
|
EP2500031A3
(de)
|
2005-02-24 |
2012-12-26 |
Joslin Diabetes Center, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Gefäßpermeabilität
|
PL1866414T3
(pl)
|
2005-03-31 |
2012-10-31 |
Calando Pharmaceuticals Inc |
Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
|
UA95446C2
(ru)
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Мутаци в генах oas1
|
US20070031342A1
(en)
*
|
2005-06-22 |
2007-02-08 |
Nektar Therapeutics |
Sustained release microparticles for pulmonary delivery
|
US20110178092A1
(en)
*
|
2005-06-22 |
2011-07-21 |
Akbar Ali |
HIV-1 Protease Inhibitors
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
CN101296704B
(zh)
|
2005-09-16 |
2012-09-05 |
科内尔研究基金会 |
用于减少cd36表达的方法
|
BRPI0618214A2
(pt)
*
|
2005-11-01 |
2011-08-23 |
Alnylam Pharmaceuticals Inc |
inibição de rnai de replicação do influenza vìrus
|
EP2395012B8
(de)
|
2005-11-02 |
2018-06-06 |
Arbutus Biopharma Corporation |
Modifizierte siRNA-Moleküle und Verwendungen davon
|
US20070190182A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
ES2594368T3
(es)
|
2005-12-08 |
2016-12-19 |
Insmed Incorporated |
Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
US7989606B2
(en)
|
2006-02-10 |
2011-08-02 |
The University Of Cincinnati |
Phosphatase inhibitor protein-1 as a regulator of cardiac function
|
KR100745833B1
(ko)
|
2006-03-06 |
2007-08-02 |
고려대학교 산학협력단 |
양이온성 골드 나노입자와 유전자의 복합체 조성물
|
US7846908B2
(en)
*
|
2006-03-16 |
2010-12-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of TGF-beta and therapeutic uses thereof
|
WO2007123777A2
(en)
*
|
2006-03-30 |
2007-11-01 |
Duke University |
Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
|
WO2007124131A2
(en)
*
|
2006-04-20 |
2007-11-01 |
The University Of North Carolina At Chapel Hill |
Hybrid nanomaterials as multimodal imaging contrast agents
|
CN101489566B
(zh)
|
2006-05-19 |
2012-04-18 |
阿尔尼拉姆医药品有限公司 |
Aha基因的RNAi调控及其治疗性应用
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
DK2053915T3
(da)
|
2006-07-26 |
2014-06-30 |
Biomarck Pharmaceuticals Ltd |
Peptider til reducering af frigørelse af inflammatoriske mediatorer
|
KR100825519B1
(ko)
*
|
2007-01-05 |
2008-04-25 |
주식회사 바이오폴리메드 |
키토산 기재 고분자 접합체 및 그 제조방법
|
US20100196455A1
(en)
*
|
2007-05-04 |
2010-08-05 |
Transave, Inc. |
Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
BRPI0811265A2
(pt)
|
2007-05-16 |
2014-09-30 |
Brigham & Womens Hospital |
Tratamento de sinucleinopatias
|
CA2713150C
(en)
|
2008-02-07 |
2016-01-05 |
Cornell University |
Methods for preventing or treating insulin resistance
|
US20110135571A1
(en)
*
|
2008-02-22 |
2011-06-09 |
Wenbin Lin |
Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
|
EP2262520B1
(de)
|
2008-02-26 |
2017-05-03 |
Cornell University |
Zusammensetzungen zur prävention und behandlung von nierenschädigung
|
CA2720473A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of epas1 inhibitors
|
WO2009129220A2
(en)
|
2008-04-14 |
2009-10-22 |
The Gereral Hospital Corporation |
Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
EP2294184A4
(de)
|
2008-06-30 |
2013-03-06 |
Mesoblast Inc |
Behandlung von augenerkrankungen und exzessiver neovaskularisation mithilfe einer kombinierten therapie
|
US20110208064A1
(en)
|
2008-07-31 |
2011-08-25 |
Ran Chongzhao |
Curcumin Derivatives for Amyloid-Beta Plaque Imaging
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
WO2010051530A2
(en)
|
2008-10-31 |
2010-05-06 |
The General Hospital Corporation |
Compositions and methods for delivering a substance to a biological target
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
WO2010105096A2
(en)
|
2009-03-11 |
2010-09-16 |
University Of Massachusetts |
Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
|
WO2010120431A2
(en)
*
|
2009-03-20 |
2010-10-21 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Methods for the prevention and treatment of burn injuries and secondary complications
|
JP2010251707A
(ja)
*
|
2009-03-27 |
2010-11-04 |
Fujitsu Ltd |
配線基板及び半導体装置
|
EP2756845B1
(de)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
|
US8283333B2
(en)
|
2009-07-01 |
2012-10-09 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
US20110039766A1
(en)
|
2009-08-12 |
2011-02-17 |
Szeto Hazel H |
Methods for preventing or treating metabolic syndrome
|
PL2470191T3
(pl)
|
2009-08-24 |
2014-09-30 |
Stealth Peptides Int Inc |
Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
|
EP2942060A1
(de)
|
2009-09-29 |
2015-11-11 |
Joslin Diabetes Center, Inc. |
Verwendung von Proteinkinase-C-Delta (PKCD-)Hemmern zur Behandlung von Diabetes, Adipositas und Leberverfettung
|
JP2013506696A
(ja)
|
2009-10-05 |
2013-02-28 |
コーネル ユニヴァーシティー |
心不全の予防又は処置の方法
|
PT2506857T
(pt)
|
2009-12-01 |
2018-05-14 |
Translate Bio Inc |
Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
|
EP2519248A4
(de)
|
2009-12-31 |
2013-06-26 |
Stealth Peptides Int Inc |
Verfahren zur vorbeugung oder behandlung einer gefässverschlussverletzung
|
EP3266462A1
(de)
|
2009-12-31 |
2018-01-10 |
Stealth Peptides International, Inc. |
Verfahren zur durchführung eines koronararterien-bypass-verfahrens
|
CA3008993A1
(en)
|
2010-01-25 |
2011-07-28 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
WO2011106525A2
(en)
|
2010-02-26 |
2011-09-01 |
The Brigham And Women's Hospital, Inc. |
Methods of treating cerebral amyloid angiopathy
|
EP3040080A1
(de)
|
2010-03-15 |
2016-07-06 |
Stealth Peptides International, Inc. |
Kombinationstherapien mit cyclosporin und aromatischen kationischen peptiden
|
KR20130066626A
(ko)
|
2010-04-29 |
2013-06-20 |
나스벡스 엘티디. |
항cd3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
|
EP3130599A1
(de)
|
2010-05-03 |
2017-02-15 |
Stealth Peptides International, Inc. |
Aromatische-kationische peptide und verwendungen davon
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
US9345738B2
(en)
|
2010-07-09 |
2016-05-24 |
Stealth Biotherapeutics Corp. |
Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
|
WO2012050673A1
(en)
|
2010-10-14 |
2012-04-19 |
Wisconsin Alumni Research Foundation |
Methods for the treatment of x-linked hypophosphatemia and related disorders
|
WO2012054718A2
(en)
|
2010-10-22 |
2012-04-26 |
The General Hospital Corporation |
Treating long qt syndrome
|
WO2012065182A2
(en)
|
2010-11-12 |
2012-05-18 |
University Of Massachusetts |
Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
|
EP3211001B1
(de)
|
2010-12-22 |
2020-10-07 |
The Board of Trustees of the Leland Stanford Junior University |
Superagonisten und antagonisten von interleukin-2
|
CN107219358A
(zh)
|
2011-03-24 |
2017-09-29 |
康奈尔大学 |
芳香族阳离子肽及其用途
|
EP2691515A2
(de)
|
2011-03-31 |
2014-02-05 |
President and Fellows of Harvard College |
Einmalige population aus regulatorischen t-zellen zur regulierung von geweberegeneration und wundheilung
|
EP2729157B1
(de)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
|
US9693957B2
(en)
|
2011-07-08 |
2017-07-04 |
The University Of North Carolina At Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
CN103987397A
(zh)
|
2011-09-29 |
2014-08-13 |
梅约医学教育与研究基金会 |
芳族阳离子肽和使用它们的方法
|
GB201118704D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Univ Oxford |
Cystic fibrosis treatment
|
US20150240238A1
(en)
|
2011-11-17 |
2015-08-27 |
The Regents Of The University Of California |
Therapeutic rna switches compositions and methods of use
|
EP2788013A4
(de)
|
2011-12-09 |
2015-08-19 |
Stealth Peptides Int Inc |
Aromatisch-kationische peptide und verwendungen davon
|
JP2015509500A
(ja)
|
2012-02-22 |
2015-03-30 |
ステルス ペプチドズ インターナショナル インコーポレイテッド |
眼疾患を予防または治療するための方法および組成物
|
CA2865409C
(en)
|
2012-02-23 |
2020-07-21 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
WO2013138338A2
(en)
|
2012-03-12 |
2013-09-19 |
Massachusetts Institute Of Technology |
Methods for treating tissue damage associated with ischemia with apoliporotein d
|
EP2836514A4
(de)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
Tiki-inhibitoren
|
JP6402097B2
(ja)
|
2012-05-21 |
2018-10-10 |
インスメッド インコーポレイテッド |
肺感染症を処置するためのシステム
|
JP6561378B2
(ja)
*
|
2012-06-08 |
2019-08-21 |
トランスレイト バイオ, インコーポレイテッド |
非肺標的細胞へのmRNAの経肺送達
|
AU2013296494B2
(en)
|
2012-08-02 |
2018-04-26 |
Stealth Biotherapeutics Inc. |
Methods for treatment of atherosclerosis
|
US9738623B2
(en)
|
2012-08-06 |
2017-08-22 |
The General Hospital Corporation |
Curcumin analogs
|
JP2015530387A
(ja)
|
2012-09-04 |
2015-10-15 |
エライゾン ファーマシューティカルズ, エルエルシー |
脂質複合体化シスプラチンによる肺癌の再発防止
|
AU2013334788A1
(en)
|
2012-10-22 |
2015-06-04 |
Henry Ford Health Systems |
Methods for reducing risks associated with heart failure and factors associated therewith
|
US9902705B2
(en)
|
2012-10-24 |
2018-02-27 |
The General Hospital Corporation |
Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
|
US10124066B2
(en)
|
2012-11-29 |
2018-11-13 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
JP2016506391A
(ja)
|
2012-12-06 |
2016-03-03 |
ステルス ペプチドズ インターナショナル インコーポレイテッド |
ペプチド治療薬およびその使用方法
|
US9744210B2
(en)
|
2012-12-27 |
2017-08-29 |
Massachusetts Eye & Ear Infirmary |
Treatment of rhinosinusitis with P-glycoprotein inhibitors
|
EP2943190B1
(de)
|
2013-01-11 |
2019-01-02 |
Massachusetts Eye & Ear Infirmary |
Cyp450-lipid-metaboliten zur unterdrückung von entzündungen und angiogenese
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
EP2958585A1
(de)
|
2013-02-22 |
2015-12-30 |
Sanofi |
Serpine: verfahren zur therapeutischen beta-zellen-regeneration und -funktion
|
CN117752766A
(zh)
|
2013-03-01 |
2024-03-26 |
康德生物医疗有限公司 |
治疗线粒体疾病的方法
|
CN115990241A
(zh)
|
2013-03-01 |
2023-04-21 |
康德生物医疗有限公司 |
预防或治疗巴斯综合征的方法和组合物
|
WO2014159878A2
(en)
|
2013-03-13 |
2014-10-02 |
Regents Of The University Of California |
Intranasal administration of guanidinylated aminoglycosides
|
WO2014160221A1
(en)
|
2013-03-13 |
2014-10-02 |
The General Hospital Corporation |
Photoswitchable hdac inhibitors
|
MX362489B
(es)
|
2013-03-14 |
2019-01-21 |
Onyx Therapeutics Inc |
Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa.
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
EP2971153B1
(de)
|
2013-03-15 |
2018-10-10 |
The General Hospital Corporation |
Glycin, mitochondrialer ein-kohlenstoffmetabolismus und krebs
|
EP3586864A1
(de)
|
2013-05-14 |
2020-01-01 |
Stealth Biotherapeutics Corp |
Verfahren zur vorbeugung oder behandlung von linksventrikulärer remodellierung
|
US9737525B2
(en)
|
2013-06-07 |
2017-08-22 |
The General Hospital Corporation |
Small molecule activators of NRF2 pathway
|
CA2916497C
(en)
|
2013-06-26 |
2022-07-12 |
Stealth Biotherapeutics Corp |
Methods for the regulation of matrix metalloproteinase expression
|
US9877997B2
(en)
|
2013-06-26 |
2018-01-30 |
Stealth Biotherapeutics Corp |
Methods and compositions for regulating SRCA2A expression levels in myocardial infarction
|
US10047395B2
(en)
|
2013-06-26 |
2018-08-14 |
Stealth Biotherapeutics Corp |
Methods and compositions for detecting and diagnosing diseases and conditions
|
WO2014210056A1
(en)
|
2013-06-27 |
2014-12-31 |
Stealth Peptides International, Inc. |
Peptide therapeutics and methods for using same
|
WO2015017861A1
(en)
|
2013-08-02 |
2015-02-05 |
Stealth Peptides International, Inc. |
Methods and compositions for the prevention and treatment of friedreich's ataxia
|
US9757477B2
(en)
|
2013-09-06 |
2017-09-12 |
The General Hospital Corporation |
Imaging brown adipose tissue with curcumin derivatives
|
US10781242B2
(en)
|
2013-09-24 |
2020-09-22 |
Medicenna Therapeutics Inc. |
Interleukin-2 fusion proteins and uses thereof
|
JP6590802B2
(ja)
|
2013-11-06 |
2019-10-16 |
ザ ユニバーシティ オブ シカゴThe University Of Chicago |
化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
|
US9943563B2
(en)
|
2013-12-02 |
2018-04-17 |
Stealth Biotherapeutics Corp |
Compositions and methods for treating vitiligo
|
US10533044B2
(en)
|
2014-01-06 |
2020-01-14 |
The General Hospital Corporation |
Integrin Antagonists
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
PT3142643T
(pt)
|
2014-05-15 |
2019-10-28 |
Insmed Inc |
Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
|
EP3143166A4
(de)
|
2014-05-16 |
2018-04-18 |
University of Massachusetts |
Behandlung von chronischer myelogener leukämie (cml)
|
EP3501532A3
(de)
|
2014-05-28 |
2019-07-17 |
Stealth BioTherapeutics Corp |
Therapeutische zusammensetzungen mit frataxin, lactoferrin, sowie mitochondrialen energieerzeugungsenzymen und verwendungen davon
|
EP3502132A1
(de)
|
2014-05-28 |
2019-06-26 |
Stealth BioTherapeutics Corp |
Therapeutische zusammensetzungen mit kleinen therapeutischen molekülen und verwendungen davon
|
CA2951162C
(en)
|
2014-06-04 |
2019-04-23 |
Tersus Pharmaceuticals, LLC |
Methods of treating chronic dry eye disease using c16:1n7-palmitoleate and derivatives thereof
|
AU2015274367B2
(en)
|
2014-06-13 |
2020-11-26 |
Beth Israel Deaconess Medical Center, Inc. |
Products and methods to isolate mitochondria
|
WO2015195737A1
(en)
|
2014-06-17 |
2015-12-23 |
Stealth Peptides International, Inc. |
Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
|
EP3169310A1
(de)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
|
WO2016025480A1
(en)
|
2014-08-11 |
2016-02-18 |
The General Hospital Corporation |
Cyclooctenes for bioorthogonol reactions
|
EP3182989B1
(de)
|
2014-08-21 |
2021-04-14 |
Stealth Biotherapeutics Corp |
Peptid d-arg-2',6'-dmt-lys-phe-nh2 zur behandlung von alport-syndrom
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
US10806694B2
(en)
|
2014-10-14 |
2020-10-20 |
The University Of Chicago |
Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
|
CN110731961A
(zh)
|
2014-10-14 |
2020-01-31 |
芝加哥大学 |
金属有机框架、药物制剂及其在制备药物中的用途
|
EP3218356B1
(de)
|
2014-11-10 |
2022-11-30 |
Evrys Bio, LLC |
Anti-hcmv-zusammensetzungen und -verfahren
|
MX2017006043A
(es)
|
2014-11-10 |
2018-02-13 |
Forge Life Science Llc |
Metodo y composiciones de anti-hcmv.
|
WO2016077382A2
(en)
|
2014-11-11 |
2016-05-19 |
Massachusetts Eye & Ear Infirmary |
Conjunctivitis vaccines
|
ES2747842T3
(es)
|
2014-12-15 |
2020-03-11 |
Dicerna Pharmaceuticals Inc |
Acidos nucleicos de doble hebra modificados por ligando
|
AU2016206965B2
(en)
|
2015-01-12 |
2021-03-04 |
Children's Medical Center Corporation |
Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
ES2755725T3
(es)
|
2015-04-08 |
2020-04-23 |
Us Health |
Terapia génica viral como tratamiento para una enfermedad o un trastorno por almacenamiento de colesterol
|
CA2985235A1
(en)
|
2015-05-07 |
2016-11-10 |
Shire Human Genetic Therapies, Inc. |
Glucocerebrosidase gene therapy for parkinson's disease
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
HUE053914T2
(hu)
|
2015-09-09 |
2021-07-28 |
Novartis Ag |
Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
WO2017059338A1
(en)
|
2015-10-02 |
2017-04-06 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
EP3399993B1
(de)
|
2016-01-06 |
2021-03-31 |
D. Travis Wilson |
Verfahren zur behandlung von duchenne-muskeldystrophie
|
WO2017123933A1
(en)
|
2016-01-15 |
2017-07-20 |
Massachusetts Eye And Ear Infirmary |
Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
AU2017267969A1
(en)
|
2016-05-19 |
2018-12-13 |
Stealth Biotherapeutics Inc. |
Compositions and methods for the prevention and treatment of mitochondrial myopathies
|
US11246877B2
(en)
|
2016-05-20 |
2022-02-15 |
The University Of Chicago |
Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
|
WO2017218355A1
(en)
|
2016-06-15 |
2017-12-21 |
Counterpoint Biomedica Llc |
Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
|
US10449230B2
(en)
|
2016-10-06 |
2019-10-22 |
The Regents Of The University Of California |
Polymyxin derived cell penetrating scaffolds
|
US11471515B2
(en)
|
2016-11-09 |
2022-10-18 |
The Brigham And Women's Hospital, Inc. |
Restoration of tumor suppression using MRNA-based delivery system
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
WO2018104909A2
(en)
|
2016-12-09 |
2018-06-14 |
St. Jude Children's Research Hospital |
Dna methylation profiling for t-cell immunotherapy
|
US11359001B2
(en)
|
2016-12-09 |
2022-06-14 |
Akston Biosciences Corporation |
Insulin-Fc fusions and methods of use
|
US10913779B2
(en)
|
2017-01-25 |
2021-02-09 |
Counterpoint Biomedica Llc |
Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Mcl−1タンパク質を阻害する化合物
|
CA3067909A1
(en)
|
2017-06-19 |
2018-12-27 |
Medicenna Therapeutics Inc. |
Uses and methods for il-2 superagonists, agonists, and fusions thereof
|
US20200377906A1
(en)
|
2017-06-20 |
2020-12-03 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
|
EP3644964B1
(de)
|
2017-06-28 |
2024-04-10 |
Children's Medical Center Corporation |
Förderung des lungenwachstums
|
JP2020530986A
(ja)
|
2017-07-27 |
2020-11-05 |
ノバルティス アーゲー |
シェダーゼ耐性trem2変異体
|
BR102017016440A2
(pt)
*
|
2017-07-31 |
2019-03-19 |
Universidade Federal Do Rio Grande Do Sul |
Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
|
JP7364552B2
(ja)
|
2017-08-02 |
2023-10-18 |
ザ ユニバーシティ オブ シカゴ |
X線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート
|
JP2020530457A
(ja)
|
2017-08-08 |
2020-10-22 |
メモリアル スローン ケタリング キャンサー センター |
Mek阻害剤治療によって惹起される皮膚反応を治療するbraf阻害剤の使用
|
EP3664834A1
(de)
|
2017-08-11 |
2020-06-17 |
Dana Farber Cancer Institute, Inc. |
Verwendung eines botulinumtoxinmittels zur behandlung von plasmazellstörungen
|
WO2019036375A1
(en)
|
2017-08-14 |
2019-02-21 |
Sanford Burnham Prebys Medical Discovery Institute |
CARDIOGENIC MESODERMA TRAINING REGULATORS
|
US11364248B2
(en)
|
2017-08-18 |
2022-06-21 |
Amgen Inc. |
Compounds that inhibit Mcl-1 protein
|
US11279712B2
(en)
|
2017-08-29 |
2022-03-22 |
Amgen Inc. |
Macrocyclic compounds that inhibit MCL-1 protein
|
WO2019046668A1
(en)
|
2017-08-31 |
2019-03-07 |
Kezar Life Sciences |
AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
|
AU2018350999B2
(en)
|
2017-10-18 |
2022-09-08 |
Evrys Bio, Llc |
Broad spectrum antiviral compositions and methods
|
US11674125B2
(en)
|
2017-12-18 |
2023-06-13 |
The General Hospital Corporation |
Glycoengineering
|
WO2019143969A1
(en)
|
2018-01-18 |
2019-07-25 |
Claudio Maldonado |
Treating microvascular dysfunction
|
WO2019155387A1
(en)
|
2018-02-07 |
2019-08-15 |
St. Jude Children's Research Hospital |
Epigenetic histone regulation mediated by cxorf67
|
WO2019169202A1
(en)
|
2018-02-28 |
2019-09-06 |
The Johns Hopkins University |
Bacterial biofilms and cancer
|
MA54985A
(fr)
|
2018-03-05 |
2021-12-29 |
Amgen Inc |
Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
|
EP3773505A4
(de)
|
2018-03-30 |
2021-12-22 |
Insmed Incorporated |
Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
|
US20190314324A1
(en)
|
2018-04-13 |
2019-10-17 |
The University Of Chicago |
Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
|
EP3790968A1
(de)
|
2018-05-11 |
2021-03-17 |
Alpha Anomeric SAS |
Oligonukleotidkonjugate mit 7'-5'-alpha-anomerisch-bicyclischen zuckernukleosiden
|
US11925690B2
(en)
|
2018-06-13 |
2024-03-12 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeting Rpn11
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
EP3807263A1
(de)
|
2018-06-13 |
2021-04-21 |
Amphista Therapeutics Ltd |
Bifunktionale moleküle zum targeting von uchl5
|
US20210230545A1
(en)
|
2018-07-09 |
2021-07-29 |
St. Jude Children's Research Hospital |
Use of il-12 to alter epigenetic effector programs in cd8 t cells
|
US20220073883A1
(en)
|
2018-07-25 |
2022-03-10 |
The Johns Hopkins University |
Compositions and methods for generation of heart field-specific progenitor cells
|
EP3843845A4
(de)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CA3116321A1
(en)
|
2018-10-16 |
2020-04-23 |
The Johns Hopkins University |
Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
|
WO2020097193A1
(en)
|
2018-11-06 |
2020-05-14 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
US11931397B2
(en)
|
2018-12-06 |
2024-03-19 |
Stealth Biotherapeutics Inc. |
Methods and compositions for the treatment of Sengers syndrome
|
WO2020170231A1
(en)
|
2019-02-22 |
2020-08-27 |
St. Jude Children's Research Hospital |
Methods for identifying and improving t cell multipotency
|
SG11202109392YA
(en)
|
2019-02-28 |
2021-09-29 |
Kezar Life Sciences |
Thiazole derivatives as protein secretion inhibitors
|
US20220395531A1
(en)
|
2019-04-15 |
2022-12-15 |
Children`S Medical Center Corporation |
Aerosolized compositions comprising mitochondria and methods of use thereof
|
WO2020237491A1
(en)
|
2019-05-28 |
2020-12-03 |
Shanghaitech University |
Composition and methods to treat ectodermal dysplasia 2, clouston type
|
JP2022542882A
(ja)
|
2019-07-24 |
2022-10-07 |
ステルス バイオセラピューティクス インコーポレイテッド |
神経変性疾患の治療におけるペプチド模倣化合物(r)-2-アミノ-n-((s)-l-(((s)-5-アミノ-l-(3-ベンジル-1,2,4-オキサジアゾール-5-イル)ペンチル)アミノ)-3-(4-ヒドロキシ-2,6-ジメチルフェニル)-i-オキソプロパン-2-イル)-5-グアニジノペンタンアミド
|
CA3156499A1
(en)
|
2019-10-04 |
2021-04-08 |
Stealth Biotherapeutics Inc. |
CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
|
MX2022004352A
(es)
|
2019-10-17 |
2022-07-19 |
Stridebio Inc |
Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
|
WO2021146436A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
KR20220141299A
(ko)
|
2020-01-14 |
2022-10-19 |
신테카인, 인크. |
Il2 오르토로그 및 사용 방법
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
CN115996916A
(zh)
|
2020-04-03 |
2023-04-21 |
康德生物医疗有限公司 |
用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法
|
CA3173673A1
(en)
|
2020-04-23 |
2021-10-28 |
The Regents Of The University Of California |
Genetically engineered phagocytes, and related compositions, vectors, methods and systems
|
IL299744A
(en)
|
2020-07-30 |
2023-03-01 |
Tiziana Life Sciences Plc |
Antibodies to CD-3 for the treatment of the corona virus
|
WO2022031885A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10ra binding molecules and methods of use
|
US20230272094A1
(en)
|
2020-08-05 |
2023-08-31 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
IL300736A
(en)
|
2020-08-31 |
2023-04-01 |
Kezar Life Sciences |
Protein secretion inhibitors
|
AU2021376354A1
(en)
|
2020-11-04 |
2023-06-22 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
IL303195A
(en)
|
2020-11-25 |
2023-07-01 |
Akagera Medicines Inc |
Lipid nanoparticles for delivery of nucleic acids and related methods of use
|
CA3210753A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
CA3234994A1
(en)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Methods of suppressing microglial activation
|
WO2023069255A1
(en)
|
2021-10-20 |
2023-04-27 |
Stealth Biotherapeutics Inc. |
Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
|
WO2023101963A2
(en)
|
2021-11-30 |
2023-06-08 |
Northwestern University |
Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
|
WO2023133321A1
(en)
|
2022-01-10 |
2023-07-13 |
Stealth Biotherapeutics Inc. |
Small molecule peptidomimetic for the treatment of tauopathies
|
WO2023164250A1
(en)
|
2022-02-28 |
2023-08-31 |
Kezar Life Sciences |
Sec61 inhibitors and use thereof
|
WO2023198757A1
(en)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
|
GB202214445D0
(en)
*
|
2022-09-30 |
2022-11-16 |
Imp College Innovations Ltd |
Gene therapy
|